Deprecated: Creation of dynamic property WhitelabelOptions::$_title is deprecated in /home/grassnews/public_html/wp-content/themes/zox-news/admin/admin-page.php on line 79
Sierra Metals Reports Consolidated Financial Results for the First Quarter of 2019 Conference Call May 14, 2019 AT 10:30 AM (EDT) – GrassNews
Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Sierra Metals Reports Consolidated Financial Results for the First Quarter of 2019 Conference Call May 14, 2019 AT 10:30 AM (EDT)

Published

on

Reading Time: 13 minutes

(All $ figures reported in USD)

  • Adjusted EBITDA of $12.0 million in Q1 2019 decreased from $27.4
    million in Q1 2018
  • Operating cash flows before movements in working capital of $11.8
    million in Q1 2019 decreased from $27.4 million in Q1 2018
  • Revenue from metals payable of $49.2 million in Q1 2019 decreased
    from $61.7 million in Q1 2018 due to lower throughput and lower
    realized metal prices
  • Q1 2019 consolidated copper production of 7.7 million pounds,
    consolidated silver production of 0.7 million ounces, consolidated
    zinc production of 16.4 million pounds, consolidated lead production
    of 7.0 million pounds, and consolidated gold production of 1,986
    ounces; a 4% decrease, 16% increase, 10% decrease, a 10% increase, and
    a 2% increase respectively, compared to Q1 2018, management expects
    that annual production guidance will still be met
    (1)
  • Record quarterly throughput at the Cusi Mine in Mexico
  • $23.9 million of cash and cash equivalents as at March 31, 2019
  • Net Debt of $45.0 million as at March 31, 2019
  • The Company through its Normal Course Issuer Bid has to date
    repurchased and cancelled a total of 907,266 shares at an average VWAP
    of C$2.04
  • Shareholder conference call to be held Tuesday, May 14, 2019, at
    10:30 AM (EST)

(1) Silver equivalent ounces and copper and zinc equivalent pounds
for Q1 2019 were calculated using the following realized prices:
$15.57/oz Ag, $2.85/lb Cu, $0.94/lb Pb, $1.23/lb Zn, $1,305/oz Au.
Silver equivalent ounces and copper and zinc equivalent pounds for Q1
2018 were calculated using the following realized prices: $16.75/oz Ag,
$3.14/lb Cu, $1.15/lb Pb, $1.56/lb Zn, $1,334/oz Au.

TORONTO–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/Capex?src=hash” target=”_blank”gt;#Capexlt;/agt;–Sierra Metals Inc. (TSX:SMT)(BVL:SMT)(NYSE American:SMTS)
(“Sierra Metals” or the “Company”) today reported revenue of $49.2
million and adjusted EBITDA of $12.0 million on throughput of 568,401
tonnes and metal production of 4.0 million silver equivalent ounces, or
21.8 million copper equivalent pounds, or 50.6 million zinc equivalent
pounds for the three month period ended March 31, 2019.

The Company has continued to be successful in maintaining positive
operating cash flow generation from its existing operations in order to
reduce debt levels, fund required capital expenditures, and maintain
liquidity.

Despite the loss of 12 days of production at the Yauricocha Mine during
March 2019 due to the illegal strike action which has subsequently been
resolved, the mine continued its strong operational performance during
Q1 2019, realizing an increase in zinc equivalent metal production
compared to Q1 2018. The revenues and Adjusted EBITDA generated during
Q1 2019 allowed the Company to fund its capital expenditure programs and
repay some of the existing debt obligations, despite a challenging metal
price environment.

Advertisement
Stake.com

The Company achieved record quarterly throughput from the Cusi Mine, and
the third highest quarterly throughput from the Bolivar Mine, continuing
the successful production increases realized in Mexico during 2018.
Consolidated production of silver increased 16% to 0.7 million ounces,
copper declined 4% to 7.7 million pounds, lead increased 10% to 7.0
million pounds, zinc declined 10% to 16.4 million pounds, and gold
increased 2% to 1,986 ounces compared to Q1 2018.

Igor Gonzales, President, and CEO of Sierra Metals stated: “The first
quarter has presented us with several challenges including an illegal
strike at Yauricocha, as well as slower than expected ramp up of
throughput at Bolivar and Cusi with lower head grades and recoveries. I
want to assure shareholders that management remains focused on the
expansions in Mexico and improving tonnage, head grades, and recovery
rates which in turn will help to lower costs. Also, as noted above, it
still bears mentioning that in Q1 2019 Yauricocha saw an increase in
zinc equivalent metal production, Cusi had record throughput and Bolivar
had a 1% increase in throughput over Q1 2018. Subsequent to Q1 2019,
throughput rates continue to improve.
At Yauricocha the strike
has been settled and the mine is working to full capacity. In Mexico,
production increases are expected to become more apparent in late Q2
2019 when we should reach higher throughput rates at both Bolivar and
Cusi. Production is also expected to be higher in the latter half of
2019 when the mines are running at the higher throughput rates. Cash
flow continues to be strong and with continued efforts, we expect to see
further improvements in cash flow and good returns on the capital being
invested. Management expects that the Company will still be within the
annual production guidance provided.

We continue to modernize and improve all our Mines, implementing best
operational practices. These improvements are expected to allow for the
Company to increase metal production over the course of the coming year.
Our Company-wide ongoing brownfield exploration programs should also
lead to further significant growth in reserves and resources, which will
add to the value of our assets during the year ahead.”

He continued, “Sierra Metals’ balance sheet remains strong with the
liquidity needed to meet our operational and growth expenditure
requirements.
The Company is on-track for further growth in 2019
based upon positive PEA studies which demonstrates robust growth
opportunities for the Company at all Mines.
We continue working
on Life of Mine plans which are expected to be completed in mid-2019.
Furthermore, NI 43-101 Technical Reports are expected to be completed
for the Yauricocha Mine by the end of Q2 2019 and for Bolivar and Cusi
Mines by the end of Q4 2019. We are very optimistic that these updated
reports will provide for additional reserves and resources at all Mines.”

The following table displays selected financial and operational
information for the three months ended March 31, 2019:

Advertisement
Stake.com
 
MDA Selected Financial Results
             
  Three Months Ended

(In thousands of dollars, except per share and cash cost
amounts, consolidated figures unless noted otherwise)

 

March 31, 2019

   

March 31, 2018

Operating  

 

     
Ore Processed / Tonnes Milled 568,401     557,710
Silver Ounces Produced (000’s) 691 594
Copper Pounds Produced (000’s) 7,732 8,090
Lead Pounds Produced (000’s) 6,954 6,312
Zinc Pounds Produced (000’s) 16,421 18,214
Gold Ounces Produced 1,986 1,952
Copper Equivalent Pounds Produced (000’s)1 21,767 23,445
Zinc Equivalent Pounds Produced (000’s)1 50,562 47,209

Silver Equivalent Ounces Produced (000’s)1

Advertisement
Stake.com

3,988

4,394
 
Cash Cost per Tonne Processed $ 51.77 $ 46.66
Cost of sales per AgEqOz $ 8.48 $ 7.15

Cash Cost per AgEqOz2

$ 8.30 $ 6.77
AISC per AgEqOz2 $ 13.71 $ 9.85
Cost of sales per CuEqLb2 $ 1.55 $ 1.34
Cash Cost per CuEqLb2 $ 1.52 $ 1.27
AISC per CuEqLb2 $ 2.51 $ 1.85
Cost of sales per ZnEqLb2 $ 0.67 $ 0.67
Cash Cost per ZnEqLb2 $ 0.66 $ 0.63
AISC per ZnEqLb2 $ 1.08 $ 0.92
 
Cash Cost per ZnEqLb (Yauricocha)2 $ 0.54

$

0.57
AISC per ZnEqLb (Yauricocha)2 $ 0.85 $ 0.82

Cash Cost per CuEqLb (Bolivar)2

$ 2.04 $ 1.29
AISC per CuEqLb (Bolivar)2 $ 3.59 $ 1.94
Cash Cost per AgEqOz (Cusi)2 $ 16.53 $ 18.34
AISC per AgEqOz (Cusi)2   $ 30.57       $ 28.33  

Financial

Advertisement
Stake.com
         
Revenues

$

49,180 $ 61,675
Adjusted EBITDA2 $ 12,041 $ 27,403
Operating cash flows before movements in working capital $ 11,804 $ 27,348
Adjusted net income attributable to shareholders2 $ 886 $ 11,187
Net income (loss) attributable to shareholders $ (1,724 ) $ 8,703
Cash and cash equivalents $ 23,937 $ 25,514
Working capital(3)   $ (19,795 )     $ (1,576 )

(1) Silver equivalent ounces and copper and
zinc equivalent pounds for Q1 2019 were calculated using the
following realized prices: $15.57/oz Ag, $2.85/lb Cu, $0.94/lb Pb,
$1.23/lb Zn, $1,305/oz Au. Silver equivalent ounces and copper and
zinc equivalent pounds for Q1 2018 were calculated using the
following realized prices: $16.75/oz Ag, $3.14/lb Cu, $1.15/lb Pb,
$1.56/lb Zn, $1,334/oz Au.

 

(2) This is a non-IFRS performance measure,
see Non-IFRS Performance Measures section of the MD&A.

(3) The decrease in working capital was due to
the Corona Acquisition Facility with BCP being classified as a
current liability, as it was repaid in full during May 2019.
 

Q1 2019 Financial Highlights

Advertisement
Stake.com

Revenue from metals payable of $49.2 million in Q1 2019 decreased by 20%
from $61.7 million in Q1 2018. The decrease in revenues was partially
due to a 14% decrease in tonnes processed at the Yauricocha Mine due to
the illegal strike action initiated by members of the Union of the Mine
and Metallurgical Workers of Minera Corona on March 19, 2019; which was
partially offset by higher head grades and recoveries for all metals,
except gold head grades at Yauricocha. Lower revenues were also affected
by the decreases in the prices of silver (7%), copper (9%), zinc (21%),
lead (18%), and gold (2%). Additionally, lower copper head grades and
silver and gold recoveries realized at the Bolivar Mine resulted in a
15% decrease in revenues, while Cusi’s revenues increased by 61% due to
the 165% increase in throughput, quarter over quarter.

Yauricocha’s cash cost per zinc equivalent payable pound was $0.54 (Q1
2018 – $0.57), and AISC per zinc equivalent payable pound of $0.85 (Q1
2018 – $0.82). The increase in the AISC per zinc equivalent payable
pound for Q1 2019 compared to Q1 2018 was due to the increase in
treatment and refining charges for the zinc concentrate sold. This was
partially offset by the increase in zinc equivalent payable pounds as
the Company realized higher head grades and recoveries for all metals,
except gold head grades.

Bolivar’s cash cost per copper equivalent payable pound was $2.04 (Q1
2018 – $1.29), and AISC per copper equivalent payable pound was $3.59
(Q1 2018 – $1.94) for Q1 2019 compared to Q1 2018. The increase in the
AISC per copper equivalent payable pound during Q1 2019 compared to Q1
2018 due to higher labour and contractor costs incurred related to stope
and ramp development within the mine required to increase throughput to
the 3,600 tpd and 4,000 tpd level. The majority of these costs are
included in opex. Additionally, sustaining capital expenditures were
$3.6 million higher in Q1 2019 compared to Q1 2018 and related to the
purchase of mining equipment, mine development costs, exploration
drilling within the mine, and plant improvements required to produce
3,600 to 4,000 tpd.

Cusi’s cash cost per silver equivalent payable ounce was $16.53 (Q1 2018
– $18.34), and AISC per silver equivalent payable ounce was $30.57 (Q1
2018 – $28.32) for Q1 2019 compared to Q1 2018. AISC per silver
equivalent payable ounce increased due to higher sustaining capital
expenditures incurred due to investments made in the concentrator plant
in order to increase throughput to 1,200 tpd during Q2 2019.

Adjusted EBITDA(1) of $12.0 million for Q1 2019 decreased
compared to $27.4 million in Q1 2018. The decrease in adjusted EBITDA in
Q1 2019 was due to the decrease in revenues realized at Yauricocha and
Bolivar, mainly due to the illegal strike action at Yauricocha and a
decrease in the prices of all metals.

Advertisement
Stake.com

Cash flow generated from operations before movements in working capital
of $11.8 million for Q1 2019 decreased compared to $27.3 million in Q1
2018. The decrease in operating cash flow is mainly the result of lower
revenues generated and lower gross margins realized.

Net income (loss) attributable to shareholders for Q1 2019 was $(1.7)
million (Q1 2018: $8.7 million) or $(0.01) per share (basic and diluted)
(Q1 2018: $0.05).

Cash and cash equivalents of $23.9 million and working capital of
$(19.8) million as at March 31, 2019 compared to $21.8 million and
$(8.3) million, respectively, at the end of 2018. The decrease in
working capital was due to the Corona Acquisition Facility with BCP
being classified as a current liability, as it was repaid in full during
May 2019. Cash and cash equivalents have increased by $2.1 million
during Q1 2019 due to $1.5 million of operating cash flows, and $20.7
million drawn down from the new Senior Secured Corporate Facility, being
partially offset by capital expenditures incurred in Mexico and Peru of
$(11.3) million, $(0.1) million of share repurchases, and repayments of
loans, credit facilities and interest of $(8.7) million.

(1) This is a non-IFRS performance measure, see Non-IFRS
Performance Measures section of the MD&A.

Debt Refinancing Update

Advertisement
Stake.com

During Q1 2019 the Company announced the Closing of a $100 million
Senior Secured Corporate Credit Facility in March. The facility has a
6-year term with a 2-year grace period and has a rate of Libor +3.15%.
This facility will provide the Company with additional liquidity and
will offer financial flexibility to fund future capital projects in
Mexico as well as working capital requirements. The Company will also
use the proceeds of the Corporate Facility to repay existing debt in the
near term.

Subsequent to end of the first quarter, on May 9th, the Company repaid
the remaining $33.2 million existing on the Corona Acquisition Facility
with BCP and the $15.0 million existing on the Revolving Credit Facility
with BCP, after drawing funds from the Senior Secured Corporate Credit
Facility.

Project Development

The Company reported the resolution of the illegal strike action at the
Yauricocha Mine that ran from March 19 – April 13, 2019. During the
strike there were no material situations that took place and an
agreement was been reached whereby no contractors dismissed as part of
the contractor change will be reinstated, which was the initial reason
for the strike.

Mine development at Bolívar during Q1 2019 totaled 1,454 meters. A
portion of the meters (1,070m) were developed to prepare stopes for mine
production. The remainder of the meters (384m) were related to the
deepening of ramps and developing service ramps to be used for
ventilation and pumping in the Lower El Gallo Inferior orebody and
Bolivar West orebody.

Advertisement
Stake.com

During Q1 2019, at the Cusi property, mine development totaled 1,251
meters, which included 100 meters of ramp development at the Santa Rosa
de Lima Zone; the rest of the development related to stope preparation
in various zones within the mines.

Exploration Update

Peru:

During Q1 2019, the Company drilled 59 holes totaling 9,345 meters at
Yauricocha. The drilling included the following:

Exploration Drilling:

Advertisement
Stake.com
  • Copper Porphyry Mineralization (Central Mine Zone Level 720): 2 holes
    totaling 1,849 meters were drilled to continue to test the priority
    anomaly located in the monzonite intrusive zone, where a copper
    molybdenum mineralized porphyry was discovered earlier in the year;
    drill results continue to display the presence of a copper molybdenum
    porphyry orebody, where we have observed typical alterations, as well
    as copper mineralization disseminated in the encased rock, as veinlets
    with quartz and copper are present with molybdenum;
  • Antacaca Orebody (Level 1070 Central Mine Zone): 2 holes totaling
    1,029 meters to explore the continuity of mineralization of the
    orebody at depth; the hole confirmed the continuity of this
    mineralized orebody at depth, with magnetite mineralization with
    nodules of chalcopyrite;
  • Contacto Occidental Orebody (Level 1070 Central Mine Zone): 11 holes
    totaling 1,644 meters to explore the continuity of this high-grade
    orebody at depth; six of the drill holes had positive results and
    allowed us to confirm and define the irregularities of the gaps within
    the orebody;

Definition Drilling:

  • Esperanza (Level 1020 Central Mine Zone): 5 holes totaling 639 meters
    which confirmed the continuity of mineralization of the orebody; holes
    were executed between the sublevel development level 8 meters above
    the 1020 level;
  • Esperanza Distal (Level 1020 Central Mine Zone): 15 holes totaling
    1,661 meters to further define the continuity of this mineralized
    orebody in order to bring it into production during Q3 2019;
  • Catas (1070 Level Central Mine Zone): 13 holes totaling 1,440 meters
    to define and provide greater certainty for the continuity of the
    orebody down to the 16th floor of the 1120 level;
  • Karlita (870 Level Cachi Cachi Mine): 11 holes totaling 1,083 meters
    to provide more certainty to the resources existing on the 16th
    floor of the 920 level of the mine.

Mexico:

Bolivar

  • At Bolívar during Q1 2019, 8,240 meters were drilled from surface as
    well as diamond drilling within the mine. 1,794 meters were drilled
    within the mine in the El Gallo zone to the northwest and southeast to
    determine the continuity of the skarn orebody. Surface exploration
    drilling was performed in the Bolívar West, South extension, area with
    1,234 meters drilled, and 2,748 meters in the Bolivar West/Lylli area,
    encountering skarn intersections with some mineralization. Exploration
    drilling was started to determine the potential of the Lower Gallo
    zone to the southeast, which included 708 meters drilled which
    encountered intersections of skarn with some mineralization. 1,756
    meters of geotechnical holes were drilled to determine the type of
    rock that exists near the potential Bolivar West/Piedras Verdes plant
    tunnel project.

Cusi

  • During Q1 2019 the Company drilled 1,261 meters to support the
    development of the Santa Rosa de Lima vein in Promontorio to further
    verify the size and continuity of the orezone. In addition, 3,656
    meters of surface diamond drilling was performed to explore the depth
    of the mineralized structure of San Nicolas, San Rafael and Santa Rosa
    de Lima.

Conference Call Webcast

Sierra Metals’ senior management will host a conference call on Tuesday,
May 14, 2019, at 10:30 AM (EDT) to discuss the Company’s financial and
operating results for the three months ended March 31, 2019.

Via Webcast:

A live audio webcast of the meeting will be available on the Company’s
website:

https://event.on24.com/wcc/r/1956428/CAFED0BBE1AF315572FFBCA7456DFCF6

Advertisement
Stake.com

The webcast along with presentation slides will be archived for 180 days
on www.sierrametals.com.

Via phone:

For those who prefer to listen by phone, dial-in instructions are below.
To ensure your participation, please call approximately five minutes
before the scheduled start time of the call.

Participant Number (Toll-Free North America): (833) 245-9659
Participant
Number (Toll-Free Peru): 0800-71-476
Participant Number
(International): +1 (647) 689-4231
Conference ID: 6988769

Quality Control

Advertisement
Stake.com

All technical production data contained in this news release has been
reviewed and approved by Gordon Babcock, P.Eng., Chief Operating Officer
and a Qualified Person under National Instrument 43-101 – Standards of
Disclosure for Mineral Projects.

Americo Zuzunaga, FAusIMM CP (Mining Engineer) and Vice President of
Corporate Planning is a Qualified Person and chartered professional
qualifying as a Competent Person under the Joint Ore Reserves Committee
(JORC) Australasian Code for Reporting of Exploration Results, Mineral
Resources and Ore Reserves.

Augusto Chung, FAusIMM CP (Metallurgist) and Vice President Special
Projects and Metallurgy and a chartered professional qualifying as a
Competent Person on metallurgical processes.

About Sierra Metals

Sierra Metals Inc. is Canadian based growing polymetallic mining company
with production from its Yauricocha Mine in Peru, and its Bolivar and
Cusi Mines in Mexico. The Company is focused on increasing production
volume and growing mineral resources. Sierra Metals has recently had
several new discoveries and still has additional brownfield exploration
opportunities at all three Mines in Peru and Mexico that are within or
close proximity to the existing Mines. Additionally, the Company has
large land packages at all three Mines with several prospective regional
targets providing longer term exploration upside and mineral resource
growth potential.

Advertisement
Stake.com

The Company’s Common Shares trade on the Bolsa de Valores de Lima and on
the Toronto Stock Exchange under the symbol “SMT” and on the NYSE
American Exchange under the symbol “SMTS”.

For further information regarding Sierra Metals, please visit www.sierrametals.com.

Continue to Follow, Like and Watch our progress:

Web: www.sierrametals.com
| Twitter: sierrametals
| Facebook: SierraMetalsInc
| LinkedIn: Sierra
Metals Inc

Forward-Looking Statements

Advertisement
Stake.com

This press release contains “forward-looking information” and
“forward-looking statements” within the meaning of Canadian and U.S.
securities laws related to the Company (collectively, “forward-looking
information”). Forward-looking information includes, but is not limited
to, statements with respect to the Company’s operations, including the
anticipated developments in the Company’s operations in future periods,
the Company’s planned exploration activities, the adequacy of the
Company’s financial resources, and other events or conditions that may
occur in the future. Statements concerning mineral reserve and resource
estimates may also be considered to constitute forward-looking
statements to the extent that they involve estimates of the
mineralization that will be encountered if and when the properties are
developed or further developed. These statements relate to analyses and
other information that are based on forecasts of future results,
estimates of amounts not yet determinable and assumptions of management.
Any statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
assumptions or future events or performance (often, but not always,
using words or phrases such as “expects”, “anticipates”, “plans”,
“projects”, “estimates”, “assumes”, “intends”, “strategy”, “goals”,
“objectives”, “potential” or variations thereof, or stating that certain
actions, events or results “may”, “could”, “would”, “might” or “will” be
taken, occur or be achieved, or the negative of any of these terms and
similar expressions) are not statements of historical fact and may be
forward-looking information.

Forward-looking information is subject to a variety of risks and
uncertainties, which could cause actual events or results to differ from
those reflected in the forward-looking information, including, without
limitation, risks inherent in the mining industry including
environmental hazards, industrial accidents, unusual or unexpected
geological formations, floods, labour disruptions, explosions, cave-ins,
weather conditions and criminal activity; commodity price fluctuations;
higher operating and/or capital costs; lack of available infrastructure;
the possibility that future exploration, development or mining results
will not be consistent with the Company’s expectations; risks associated
with the estimation of mineral resources and the geology, grade and
continuity of mineral deposits and the inability to replace reserves;
fluctuations in the price of commodities used in the Company’s
operations; risks related to foreign operations; changes in laws or
policies, foreign taxation, delays or the inability to obtain necessary
governmental permits; risks relating to outstanding borrowings; issues
regarding title to the Company’s properties; risks related to
environmental regulation; litigation risks; risks related to uninsured
hazards; the impact of competition; volatility in the price of the
Company’s securities; global financial risks; inability to attract or
retain qualified employees; potential conflicts of interest; risks
related to a controlling group of shareholders; dependence on third
parties; differences in U.

Contacts

Mike McAllister
VP, Investor Relations
Sierra Metals
Inc.
+1 (416) 366-7777
info@sierrametals.com

Ed Guimaraes
CFO
Sierra Metals Inc.
+1 (416)
366-7777

Advertisement
Stake.com

Igor Gonzales
President & CEO
Sierra Metals Inc.
+1
(416) 366-7777

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

Published

on

innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.

 

 

The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.  

Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.

Advertisement
Stake.com

“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”

Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”

About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com 

Advertisement
Stake.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Advertisement
Stake.com

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html

Continue Reading

Cannabis

Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location

Published

on

  • Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
  • As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
  • Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity

CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.

The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.

“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”

Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf and MÜV dispensary banners, including Cabbage Club, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano, (the) Essence, MÜV, Savvy, BITS, Encore, and Avexia. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.

Advertisement
Stake.com

Contacts:

Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com

Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Advertisement
Stake.com

###


1 Pennsylvania Department of Transportation
2 United States Census Bureau

Continue Reading

Cannabis

Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids

Published

on

Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.

Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.

Global Minor Cannabinoids Market: Key Datapoints
 

Market Value in 2023

Advertisement
Stake.com
 

US$ 17.8 Bn

 

Market Value Forecast by 2034

 
Advertisement
Stake.com

US$ 42.3 Bn

 

Growth Rate

 

 
Advertisement
Stake.com

8.2%

 

Historical Data

 

 
Advertisement
Stake.com

2016 – 2022

 

Base Year

 

 
Advertisement
Stake.com

2023

 

Forecast Data

 

 
Advertisement
Stake.com

2024 – 2034

Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.

Get Sample Copy of the Report

The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.

The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.

Advertisement
Stake.com

The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.

Visit our Homepage

Global Minor Cannabinoids Market: Key Takeaways of the Report

  • Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
  • Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
  • In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.

Key Development:

  • In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
  • In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.

Browse Related Category Reports

Global Minor Cannabinoids Market:

  • Aurora Europe GmbH
  • BulKanna
  • CBD. INC.
  • Fresh Bros Hemp Company
  • GCM Holdings, LLC (Global Cannabinoids)
  • GenCanna.
  • High Purity Natural Products.
  • Laurelcrest
  • Mile High Labs
  • PBG Global
  • Rhizo Sciences
  • ZERO POINT EXTRACTION, LLC
  • Other Industry Participants

Global Minor Cannabinoids Market

By Product Type

Advertisement
Stake.com
  • Cannabigerol (CBG)
  • Cannabichromene (CBC)
  • Cannabinol (CBN)
  • Cannabidivarin (CBDV)
  • Tetrahydrocannabutol (THCB)
  • Tetrahydrocannabivarin (THCV)
  • Tetrahydrocannabiphorol (THCP)
  • Others

By Application

  • Pharmaceutical
    • Pain Management
    • Mental Health
    • Sleep Disorders
    • Anti-inflammatory
    • Others
  • Nutraceuticals
  • Cosmetics and Personal Care
  • Food and Beverages
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)  

Consult with Our Expert:

Jay Reynolds

The Niche Research

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808- 703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

Advertisement
Stake.com

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

Email: askanexpert@thenicheresearch.com

Website: www.thenicheresearch.com

Advertisement
Stake.com
Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: sales@hipther.agency

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania